A detailed history of Cornerstone Capital, Inc. transactions in Pfizer Inc stock. As of the latest transaction made, Cornerstone Capital, Inc. holds 18,486 shares of PFE stock, worth $493,945. This represents 0.05% of its overall portfolio holdings.

Number of Shares
18,486
Previous 17,595 5.06%
Holding current value
$493,945
Previous $492,000 8.54%
% of portfolio
0.05%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$27.7 - $31.39 $24,680 - $27,968
891 Added 5.06%
18,486 $534,000
Q2 2024

Aug 02, 2024

BUY
$25.26 - $29.6 $444,449 - $520,812
17,595 New
17,595 $492,000
Q4 2022

Feb 13, 2023

SELL
$41.75 - $54.5 $74,315 - $97,010
-1,780 Reduced 10.74%
14,800 $758,000
Q3 2022

Oct 27, 2022

BUY
$43.76 - $53.42 $62,576 - $76,390
1,430 Added 9.44%
16,580 $726,000
Q2 2022

Aug 15, 2022

SELL
$46.53 - $55.17 $20,473 - $24,274
-440 Reduced 2.82%
15,150 $794,000
Q1 2022

May 13, 2022

BUY
$45.75 - $56.69 $365,542 - $452,953
7,990 Added 105.13%
15,590 $807,000
Q4 2021

Feb 11, 2022

BUY
$41.32 - $61.25 $41,320 - $61,250
1,000 Added 15.15%
7,600 $449,000
Q3 2020

Oct 27, 2020

BUY
$31.75 - $37.25 $6,350 - $7,450
200 Added 3.13%
6,600 $242,000
Q3 2019

Nov 13, 2019

SELL
$32.49 - $42.13 $29,241 - $37,917
-900 Reduced 12.33%
6,400 $230,000
Q2 2019

Aug 14, 2019

BUY
$36.98 - $41.52 $267,365 - $300,189
7,230 Added 10328.57%
7,300 $316,000
Q1 2019

May 15, 2019

SELL
$37.5 - $41.2 $259,875 - $285,516
-6,930 Reduced 99.0%
70 $297,000
Q4 2018

Feb 11, 2019

SELL
$38.47 - $43.86 $20,004 - $22,807
-520 Reduced 6.91%
7,000 $306,000
Q2 2018

Aug 13, 2018

SELL
$32.98 - $35.16 $7,321 - $7,805
-222 Reduced 2.87%
7,520 $273,000
Q3 2017

Nov 13, 2017

BUY
$31.0 - $34.15 $240,002 - $264,389
7,742
7,742 $276,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $150B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Cornerstone Capital, Inc. Portfolio

Follow Cornerstone Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Capital, Inc. with notifications on news.